RGLSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:38):

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States...

Stats
本日の出来高	94 537.00
平均出来高	3.12M
時価総額	165.63M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.150 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.600
ATR14	$0.00800 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-14	Papadopoulos Stelios	Buy	250 000	Common Stock
2024-01-18	Calsada Crispina	Sell	5 468	Common Stock
2024-01-18	Aker Christopher Ray	Sell	5 468	Common Stock
2024-01-18	Hagan Joseph P	Sell	14 580	Common Stock
2024-01-12	Klassen Preston	Buy	120 000	Stock Option (Right to Buy)

INSIDER POWER
98.53
Last 86 transactions
Buy: 13 400 605 \| Sell: 39 678

ボリューム相関

長: 0.05 (neutral)

短: -0.85 (strong negative)

Signal:(44.015) Neutral

Regulus Therapeutics Inc 相関

10 最も正の相関
STRT	0.824

10 最も負の相関
FORE	-0.81

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Regulus Therapeutics Inc 相関 - 通貨/商品

-0.56
( weak negative )

-0.63
( weak negative )

0.00
( neutral )

0.46
( neutral )

0.52
( weak )

0.74
( moderate )

Regulus Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-227 000 (0.00 %)
EPS:	$-1.580

FY	2023
収益:	$0
総利益:	$-227 000 (0.00 %)
EPS:	$-1.580

FY	2022
収益:	$0
総利益:	$-122 000 (0.00 %)
EPS:	$-1.860

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.19

Financial Reports:

No articles found.

Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.